Literature DB >> 21963846

Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer.

L Cao1, M Shao, J Schilder, T Guise, K S Mohammad, D Matei.   

Abstract

Tissue transglutaminase (TG2), an enzyme involved in cell proliferation, differentiation and apoptosis is overexpressed in ovarian carcinomas, where it modulates epithelial-to-mesenchymal transition (EMT) and promotes metastasis. Its regulation in ovarian cancer (OC) remains unexplored. Here, we show that transforming growth factor (TGF)-β, a cytokine involved in tumor dissemination is abundantly secreted in the OC microenvironment and induces TG2 expression and enzymatic activity. This is mediated at transcriptional level by SMADs and by TGF-β-activated kinase 1-mediated activation of the nuclear factor-κB complex. TGF-β-stimulated OC cells aggregate as spheroids, which enable peritoneal dissemination. We show that TGF-β-induced TG2 regulates EMT, formation of spheroids and OC metastasis. TG2 knock-down in OC cells decreases the number of cells harboring a cancer stem cell phenotype (CD44+/CD117+). Furthermore, CD44+/CD117+ cells isolated from human ovarian tumors express high levels of TG2. In summary, TGF-β-induced TG2 enhances ovarian tumor metastasis by inducing EMT and a cancer stem cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963846     DOI: 10.1038/onc.2011.429

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  99 in total

Review 1.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

2.  Relationship between CD44high/CD133high/CD117high cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines.

Authors:  Ana Livia Silva Galbiatti-Dias; Glaucia Maria Mendonça Fernandes; Marcia Maria Urbanin Castanhole-Nunes; Luiza Fernandes Hidalgo; Carlos Henrique Viesi Nascimento Filho; Rosa Sayoko Kawasaki-Oyama; Leticia Antunes Muniz Ferreira; Patricia Matos Biselli-Chicote; Érika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

3.  miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.

Authors:  X Zhu; H Shen; X Yin; L Long; C Xie; Y Liu; L Hui; X Lin; Y Fang; Y Cao; Y Xu; M Li; W Xu; Y Li
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

4.  Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression.

Authors:  Jiyoon Lee; Salvatore Condello; Bakhtiyor Yakubov; Robert Emerson; Andrea Caperell-Grant; Kiyotaka Hitomi; Jingwu Xie; Daniela Matei
Journal:  Clin Cancer Res       Date:  2015-06-03       Impact factor: 12.531

5.  Blockade of TGF-β signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models.

Authors:  Daniel Newsted; Sunandan Banerjee; Kathleen Watt; Sarah Nersesian; Peter Truesdell; Levi L Blazer; Lia Cardarelli; Jarrett J Adams; Sachdev S Sidhu; Andrew W Craig
Journal:  Oncoimmunology       Date:  2018-11-20       Impact factor: 8.110

Review 6.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

7.  Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.

Authors:  Salvatore Condello; Livia Sima; Cristina Ivan; Horacio Cardenas; Gary Schiltz; Rama K Mishra; Daniela Matei
Journal:  Cancer Res       Date:  2018-03-06       Impact factor: 12.701

8.  Cancer stem cell and stromal microenvironment.

Authors:  Li Li; John Cole; David A Margolin
Journal:  Ochsner J       Date:  2013

9.  Prognostic role of tissue transglutaminase 2 in colon carcinoma.

Authors:  María Jesús Fernández-Aceñero; Sofía Torres; Irene Garcia-Palmero; Cristina Díaz Del Arco; J Ignacio Casal
Journal:  Virchows Arch       Date:  2016-09-13       Impact factor: 4.064

Review 10.  Transglutaminase is a tumor cell and cancer stem cell survival factor.

Authors:  Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr
Journal:  Mol Carcinog       Date:  2015-08-10       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.